27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
(Biotech stocks hitting 52-week highs on Oct. 17)
- Anixa Biosciences Inc (NASDAQ:ANIX)
Down In The Dumps
(Biotech stocks hitting 52-week lows on Oct. 17)
- Aclaris Therapeutics Inc (NASDAQ:ACRS)
- Advaxis, Inc. (NASDAQ:ADXS)
- Cleveland BioLabs, Inc. (NASDAQ:CBLI)
- Elanco Animal Health Inc (NYSE:ELAN)
- Fortress Biotech (NASDAQ:FBIO)
- Fresenius Medical Care AG & Co. (NYSE:FMS)(lowered its FY18 sales and net income guidance)
- IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI)
- KITOV PHARMA LT/S ADR (NASDAQ:KTOV)
- Moleculin Biotech Inc (NASDAQ:MBRX)
- Neuronetics Inc (NASDAQ:STIM)
- Smith & Nephew plc (NYSE:SNN)
- Translate Bio Inc (NASDAQ:TBIO)
- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
Stocks In Focus
Endocyte To Be Acquired by Novartis For $2.1 Billion; Novartis Q3 Sales, Core Earnings Rise
Endocyte, Inc. (NASDAQ:ECYT), which develops therapies for cancer treatment, announced a deal to be acquired by Novartis AG (NYSE:NVS) for $24 per share, or a total equity value of $2.1 billion in cash. The per share value represents a 54 percent premium to Endocyte's closing price Oct. 17.
Separately, Novartis reported Q3 results, showing 6-percent constant currency sales growth and core net income that came in slightly above estimates. The company also raised its full-year sales outlook.
Proteostasis Reports Positive Results For Early-stage Study Of Cystic Fibrosis Combo Therapy
Proteostasis Therapeutics Inc (NASDAQ:PTI) announced positive preliminary results from three double cohorts of its ongoing Phase 1 study of its proprietary combination therapy doublet PTI-808 and PTI-801, in treating cystic fibrosis.
The stock jumped 24.86 percent to $2.3599 in after-hours trading.
See Also: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Aclaris Prices Common Stock Offering
Aclaris said it has priced its underwritten public offering of 8.645 million shares at $10.75 per share. The company expects gross proceeds of about $92.9 million from the offering.
The stock shed 8.71 percent to $11.11 in after-hours trading.
Takeda Gets Japanese Clearance For Shire Buy
Japanese drug maker Takeda said it has received unconditional clearance from the Japanese antitrust agency for its proposed acquisition of Shire PLC (NASDAQ:SHPG). The deal has now been vetted by regulatory authorities in multiple key jurisdictions, including the U.S., China and Brazil, among others.
Adverum Confirms Patterson as CEO
Adverum Biotechnologies Inc (NASDAQ:ADVM) announced the promotion of Leone Patterson as its president and CEO. Patterson has been serving as the interim CEO since May.
Eiger Reports Positive Mid-stage Trial Results For Viral Hepatitis Therapy
Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) announced positive Phase 2 study, end-of-treatment Data for its pegylated interferon lambda monotherapy in hepatitis Delta virus infection.
The stock rallied 4.88 percent to $12.2399 in after-hours trading.
On The Radar
Earnings
- Intuitive Surgical, Inc. (NASDAQ:ISRG)(after the market close)
IPO
Osmotica Pharma priced its initial public offering, or IPO, of 6.65 million shares at $7 per share, markedly lower than the initially estimated price range of $14-$16. The shares will begin trading on the Nasdaq under the ticker symbol OSMT.
PhaseBio Pharmaceuticals priced its upsized offering of 9.2 million at $5, lower than the estimated price range of $12-$14. The biotech that develops therapies for orphan diseases will list its shares on the Nasdaq under the ticker symbol PHAS.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.